aluates Reports

$ 0.0

Automative

Global Tumor Immunity Therapy Market Research Report 2024

Published Date: April 2024

Report Code: QYRE-Auto-2K13354

Global Tumor Immunity Therapy Market Research Report 2023

BUY CHAPTERS

Global Tumor Immunity Therapy Market Research Report 2024

Code: QYRE-Auto-2K13354

Report

April 2024

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bristol–Myers Squibb

Merck& Co. Inc

Roche

Astrazeneca plc

Sanofi

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc

IMVAQ Therapeutics

Arch Oncology

Juno Therapeutics

Refuge

Lepu Biopharma

Genoimmune

TCR Cure

Tumor Immunity Therapy Market

The global Tumor Immunity Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Tumor Immunity Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Tumor Immunity Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Tumor Immunity Therapy in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity Therapy.

Report Scope

The Tumor Immunity Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumor Immunity Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Tumor Immunity Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Tumor Immunity Therapy Market Report

Report Metric	Details
Report Name	Tumor Immunity Therapy Market
Segment by Type	Immune Checkpoint Inhibitor Cytokine Immunotherapy Cancer Vaccine Car-t Cell Therapy Others
Segment by Application	Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., IMVAQ Therapeutics, Arch Oncology, Juno Therapeutics, Refuge, Lepu Biopharma, Genoimmune, TCR Cure
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunity Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Tumor Immunity Therapy Market report?

Ans: The main players in the Tumor Immunity Therapy Market are Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., IMVAQ Therapeutics, Arch Oncology, Juno Therapeutics, Refuge, Lepu Biopharma, Genoimmune, TCR Cure

What are the Application segmentation covered in the Tumor Immunity Therapy Market report?

Ans: The Applications covered in the Tumor Immunity Therapy Market report are Hospital, Clinic

What are the Type segmentation covered in the Tumor Immunity Therapy Market report?

Ans: The Types covered in the Tumor Immunity Therapy Market report are Immune Checkpoint Inhibitor, Cytokine Immunotherapy, Cancer Vaccine, Car-t Cell Therapy, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Tumor Immunity Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Immune Checkpoint Inhibitor

1.2.3 Cytokine Immunotherapy

1.2.4 Cancer Vaccine

1.2.5 Car-t Cell Therapy

1.2.6 Others

1.3 Market by Application

1.3.1 Global Tumor Immunity Therapy Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Tumor Immunity Therapy Market Perspective (2019-2030)

2.2 Tumor Immunity Therapy Growth Trends by Region

2.2.1 Global Tumor Immunity Therapy Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Tumor Immunity Therapy Historic Market Size by Region (2019-2024)

2.2.3 Tumor Immunity Therapy Forecasted Market Size by Region (2025-2030)

2.3 Tumor Immunity Therapy Market Dynamics

2.3.1 Tumor Immunity Therapy Industry Trends

2.3.2 Tumor Immunity Therapy Market Drivers

2.3.3 Tumor Immunity Therapy Market Challenges

2.3.4 Tumor Immunity Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Tumor Immunity Therapy Players by Revenue

3.1.1 Global Top Tumor Immunity Therapy Players by Revenue (2019-2024)

3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2019-2024)

3.2 Global Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Tumor Immunity Therapy Revenue

3.4 Global Tumor Immunity Therapy Market Concentration Ratio

3.4.1 Global Tumor Immunity Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunity Therapy Revenue in 2023

3.5 Tumor Immunity Therapy Key Players Head office and Area Served

3.6 Key Players Tumor Immunity Therapy Product Solution and Service

3.7 Date of Enter into Tumor Immunity Therapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor Immunity Therapy Breakdown Data by Type

4.1 Global Tumor Immunity Therapy Historic Market Size by Type (2019-2024)

4.2 Global Tumor Immunity Therapy Forecasted Market Size by Type (2025-2030)

5 Tumor Immunity Therapy Breakdown Data by Application

5.1 Global Tumor Immunity Therapy Historic Market Size by Application (2019-2024)

5.2 Global Tumor Immunity Therapy Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Tumor Immunity Therapy Market Size (2019-2030)

6.2 North America Tumor Immunity Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Tumor Immunity Therapy Market Size by Country (2019-2024)

6.4 North America Tumor Immunity Therapy Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Tumor Immunity Therapy Market Size (2019-2030)

7.2 Europe Tumor Immunity Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Tumor Immunity Therapy Market Size by Country (2019-2024)

7.4 Europe Tumor Immunity Therapy Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Tumor Immunity Therapy Market Size (2019-2030)

8.2 Asia-Pacific Tumor Immunity Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2019-2024)

8.4 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Tumor Immunity Therapy Market Size (2019-2030)

9.2 Latin America Tumor Immunity Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Tumor Immunity Therapy Market Size by Country (2019-2024)

9.4 Latin America Tumor Immunity Therapy Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Tumor Immunity Therapy Market Size (2019-2030)

10.2 Middle East & Africa Tumor Immunity Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2019-2024)

10.4 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bristol-Myers Squibb

11.1.1 Bristol-Myers Squibb Company Detail

11.1.2 Bristol-Myers Squibb Business Overview

11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Introduction

11.1.4 Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2019-2024)

11.1.5 Bristol-Myers Squibb Recent Development

11.2 Merck & Co., Inc.

11.2.1 Merck & Co., Inc. Company Detail

11.2.2 Merck & Co., Inc. Business Overview

11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Introduction

11.2.4 Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2019-2024)

11.2.5 Merck & Co., Inc. Recent Development

11.3 Roche AG

11.3.1 Roche AG Company Detail

11.3.2 Roche AG Business Overview

11.3.3 Roche AG Tumor Immunity Therapy Introduction

11.3.4 Roche AG Revenue in Tumor Immunity Therapy Business (2019-2024)

11.3.5 Roche AG Recent Development

11.4 AstraZeneca, Plc

11.4.1 AstraZeneca, Plc Company Detail

11.4.2 AstraZeneca, Plc Business Overview

11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Introduction

11.4.4 AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2019-2024)

11.4.5 AstraZeneca, Plc Recent Development

11.5 Sanofi S.A.

11.5.1 Sanofi S.A. Company Detail

11.5.2 Sanofi S.A. Business Overview

11.5.3 Sanofi S.A. Tumor Immunity Therapy Introduction

11.5.4 Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2019-2024)

11.5.5 Sanofi S.A. Recent Development

11.6 Dendreon Pharmaceuticals

11.6.1 Dendreon Pharmaceuticals Company Detail

11.6.2 Dendreon Pharmaceuticals Business Overview

11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Introduction

11.6.4 Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2019-2024)

11.6.5 Dendreon Pharmaceuticals Recent Development

11.7 Novartis

11.7.1 Novartis Company Detail

11.7.2 Novartis Business Overview

11.7.3 Novartis Tumor Immunity Therapy Introduction

11.7.4 Novartis Revenue in Tumor Immunity Therapy Business (2019-2024)

11.7.5 Novartis Recent Development

11.8 Gilead Sciences Inc.

11.8.1 Gilead Sciences Inc. Company Detail

11.8.2 Gilead Sciences Inc. Business Overview

11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Introduction

11.8.4 Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2019-2024)

11.8.5 Gilead Sciences Inc. Recent Development

11.9 IMVAQ Therapeutics

11.9.1 IMVAQ Therapeutics Company Detail

11.9.2 IMVAQ Therapeutics Business Overview

11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Introduction

11.9.4 IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2019-2024)

11.9.5 IMVAQ Therapeutics Recent Development

11.10 Arch Oncology

11.10.1 Arch Oncology Company Detail

11.10.2 Arch Oncology Business Overview

11.10.3 Arch Oncology Tumor Immunity Therapy Introduction

11.10.4 Arch Oncology Revenue in Tumor Immunity Therapy Business (2019-2024)

11.10.5 Arch Oncology Recent Development

11.11 Juno Therapeutics

11.11.1 Juno Therapeutics Company Detail

11.11.2 Juno Therapeutics Business Overview

11.11.3 Juno Therapeutics Tumor Immunity Therapy Introduction

11.11.4 Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2019-2024)

11.11.5 Juno Therapeutics Recent Development

11.12 Refuge

11.12.1 Refuge Company Detail

11.12.2 Refuge Business Overview

11.12.3 Refuge Tumor Immunity Therapy Introduction

11.12.4 Refuge Revenue in Tumor Immunity Therapy Business (2019-2024)

11.12.5 Refuge Recent Development

11.13 Lepu Biopharma

11.13.1 Lepu Biopharma Company Detail

11.13.2 Lepu Biopharma Business Overview

11.13.3 Lepu Biopharma Tumor Immunity Therapy Introduction

11.13.4 Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2019-2024)

11.13.5 Lepu Biopharma Recent Development

11.14 Genoimmune

11.14.1 Genoimmune Company Detail

11.14.2 Genoimmune Business Overview

11.14.3 Genoimmune Tumor Immunity Therapy Introduction

11.14.4 Genoimmune Revenue in Tumor Immunity Therapy Business (2019-2024)

11.14.5 Genoimmune Recent Development

11.15 TCR Cure

11.15.1 TCR Cure Company Detail

11.15.2 TCR Cure Business Overview

11.15.3 TCR Cure Tumor Immunity Therapy Introduction

11.15.4 TCR Cure Revenue in Tumor Immunity Therapy Business (2019-2024)

11.15.5 TCR Cure Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Bristol–Myers Squibb

Merck& Co. Inc

Roche

Astrazeneca plc

Sanofi

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc

IMVAQ Therapeutics

Arch Oncology

Juno Therapeutics

Refuge

Lepu Biopharma

Genoimmune

TCR Cure

List of Tables

Table 1. Global Tumor Immunity Therapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Immune Checkpoint Inhibitor

Table 3. Key Players of Cytokine Immunotherapy

Table 4. Key Players of Cancer Vaccine

Table 5. Key Players of Car-t Cell Therapy

Table 6. Key Players of Others

Table 7. Global Tumor Immunity Therapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Tumor Immunity Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Tumor Immunity Therapy Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Tumor Immunity Therapy Market Share by Region (2019-2024)

Table 11. Global Tumor Immunity Therapy Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Tumor Immunity Therapy Market Share by Region (2025-2030)

Table 13. Tumor Immunity Therapy Market Trends

Table 14. Tumor Immunity Therapy Market Drivers

Table 15. Tumor Immunity Therapy Market Challenges

Table 16. Tumor Immunity Therapy Market Restraints

Table 17. Global Tumor Immunity Therapy Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Tumor Immunity Therapy Market Share by Players (2019-2024)

Table 19. Global Top Tumor Immunity Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2023)

Table 20. Ranking of Global Top Tumor Immunity Therapy Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Tumor Immunity Therapy Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Tumor Immunity Therapy Product Solution and Service

Table 24. Date of Enter into Tumor Immunity Therapy Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Tumor Immunity Therapy Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Tumor Immunity Therapy Revenue Market Share by Type (2019-2024)

Table 28. Global Tumor Immunity Therapy Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Tumor Immunity Therapy Revenue Market Share by Type (2025-2030)

Table 30. Global Tumor Immunity Therapy Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Tumor Immunity Therapy Revenue Market Share by Application (2019-2024)

Table 32. Global Tumor Immunity Therapy Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Tumor Immunity Therapy Revenue Market Share by Application (2025-2030)

Table 34. North America Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Tumor Immunity Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Tumor Immunity Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Tumor Immunity Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Tumor Immunity Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Tumor Immunity Therapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Tumor Immunity Therapy Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Tumor Immunity Therapy Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Tumor Immunity Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Tumor Immunity Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Tumor Immunity Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Tumor Immunity Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 49. Bristol-Myers Squibb Company Detail

Table 50. Bristol-Myers Squibb Business Overview

Table 51. Bristol-Myers Squibb Tumor Immunity Therapy Product

Table 52. Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 53. Bristol-Myers Squibb Recent Development

Table 54. Merck & Co., Inc. Company Detail

Table 55. Merck & Co., Inc. Business Overview

Table 56. Merck & Co., Inc. Tumor Immunity Therapy Product

Table 57. Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 58. Merck & Co., Inc. Recent Development

Table 59. Roche AG Company Detail

Table 60. Roche AG Business Overview

Table 61. Roche AG Tumor Immunity Therapy Product

Table 62. Roche AG Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 63. Roche AG Recent Development

Table 64. AstraZeneca, Plc Company Detail

Table 65. AstraZeneca, Plc Business Overview

Table 66. AstraZeneca, Plc Tumor Immunity Therapy Product

Table 67. AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 68. AstraZeneca, Plc Recent Development

Table 69. Sanofi S.A. Company Detail

Table 70. Sanofi S.A. Business Overview

Table 71. Sanofi S.A. Tumor Immunity Therapy Product

Table 72. Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 73. Sanofi S.A. Recent Development

Table 74. Dendreon Pharmaceuticals Company Detail

Table 75. Dendreon Pharmaceuticals Business Overview

Table 76. Dendreon Pharmaceuticals Tumor Immunity Therapy Product

Table 77. Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 78. Dendreon Pharmaceuticals Recent Development

Table 79. Novartis Company Detail

Table 80. Novartis Business Overview

Table 81. Novartis Tumor Immunity Therapy Product

Table 82. Novartis Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 83. Novartis Recent Development

Table 84. Gilead Sciences Inc. Company Detail

Table 85. Gilead Sciences Inc. Business Overview

Table 86. Gilead Sciences Inc. Tumor Immunity Therapy Product

Table 87. Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 88. Gilead Sciences Inc. Recent Development

Table 89. IMVAQ Therapeutics Company Detail

Table 90. IMVAQ Therapeutics Business Overview

Table 91. IMVAQ Therapeutics Tumor Immunity Therapy Product

Table 92. IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 93. IMVAQ Therapeutics Recent Development

Table 94. Arch Oncology Company Detail

Table 95. Arch Oncology Business Overview

Table 96. Arch Oncology Tumor Immunity Therapy Product

Table 97. Arch Oncology Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 98. Arch Oncology Recent Development

Table 99. Juno Therapeutics Company Detail

Table 100. Juno Therapeutics Business Overview

Table 101. Juno Therapeutics Tumor Immunity Therapy Product

Table 102. Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 103. Juno Therapeutics Recent Development

Table 104. Refuge Company Detail

Table 105. Refuge Business Overview

Table 106. Refuge Tumor Immunity Therapy Product

Table 107. Refuge Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 108. Refuge Recent Development

Table 109. Lepu Biopharma Company Detail

Table 110. Lepu Biopharma Business Overview

Table 111. Lepu Biopharma Tumor Immunity Therapy Product

Table 112. Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 113. Lepu Biopharma Recent Development

Table 114. Genoimmune Company Detail

Table 115. Genoimmune Business Overview

Table 116. Genoimmune Tumor Immunity Therapy Product

Table 117. Genoimmune Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 118. Genoimmune Recent Development

Table 119. TCR Cure Company Detail

Table 120. TCR Cure Business Overview

Table 121. TCR Cure Tumor Immunity Therapy Product

Table 122. TCR Cure Revenue in Tumor Immunity Therapy Business (2019-2024) & (US$ Million)

Table 123. TCR Cure Recent Development

Table 124. Research Programs/Design for This Report

Table 125. Key Data Information from Secondary Sources

Table 126. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Tumor Immunity Therapy Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Tumor Immunity Therapy Market Share by Type: 2023 VS 2030

Figure 3. Immune Checkpoint Inhibitor Features

Figure 4. Cytokine Immunotherapy Features

Figure 5. Cancer Vaccine Features

Figure 6. Car-t Cell Therapy Features

Figure 7. Others Features

Figure 8. Global Tumor Immunity Therapy Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Tumor Immunity Therapy Market Share by Application: 2023 VS 2030

Figure 10. Hospital Case Studies

Figure 11. Clinic Case Studies

Figure 12. Tumor Immunity Therapy Report Years Considered

Figure 13. Global Tumor Immunity Therapy Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Tumor Immunity Therapy Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Tumor Immunity Therapy Market Share by Region: 2023 VS 2030

Figure 16. Global Tumor Immunity Therapy Market Share by Players in 2023

Figure 17. Global Top Tumor Immunity Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Tumor Immunity Therapy Revenue in 2023

Figure 19. North America Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Tumor Immunity Therapy Market Share by Country (2019-2030)

Figure 21. United States Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Tumor Immunity Therapy Market Share by Country (2019-2030)

Figure 25. Germany Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Tumor Immunity Therapy Market Share by Region (2019-2030)

Figure 33. China Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Tumor Immunity Therapy Market Share by Country (2019-2030)

Figure 41. Mexico Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Tumor Immunity Therapy Market Share by Country (2019-2030)

Figure 45. Turkey Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Tumor Immunity Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 48. Merck & Co., Inc. Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 49. Roche AG Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 50. AstraZeneca, Plc Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 51. Sanofi S.A. Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 52. Dendreon Pharmaceuticals Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 53. Novartis Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 54. Gilead Sciences Inc. Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 55. IMVAQ Therapeutics Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 56. Arch Oncology Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 57. Juno Therapeutics Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 58. Refuge Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 59. Lepu Biopharma Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 60. Genoimmune Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 61. TCR Cure Revenue Growth Rate in Tumor Immunity Therapy Business (2019-2024)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Immuno Oncology Treatment Market Insights Forecast to 2030

Global Health Product for Immune Market Research Report 2024

Cancer Immunotherapy Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anti tumor Drug Market Research Report 2025

Global Adjuvant Therapy Market Research Report 2024

Global Pembrolizumab Market Research Report 2024

Global Immune Adjuvant Market Research Report 2024

Global Immune Checkpoint Agents Market Research Report 2025

Global Oncology and Cancer Treatment Drug Market Research Report 2024

Global Cancer Immunomodulator Market Research Report 2025

Neoantigen Cancer Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Nivolumab Market Research Report 2024

Global Antibodies in Oncology Market Research Report 2024

Tumor Immunotherapy Market

Global Allergy Immunotherapies Market Research Report 2025

Global Novel T Cell Immunotherapies Market Research Report 2024

Global Cancer Insurance Market Research Report 2024

Global Emerging Cancer Vaccines Market Insights Forecast to 2030

Global Anticancer Injection Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions